Journal of Immunology Research / 2018 / Article / Tab 2

Research Article

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients

Table 2

Patients’ characteristics during ACT.

PatientSexAgePSLDH levelAJCC stageBiopsy site used for TIL extractionSize of excised tumor (cm3)TIL infusionTIL amount injected (109)MetastasesResponseAdverse eventsPFS (months)OS (months)
YearnGrade 1-2Grade 3

1F1702 NIVSCnod6200928.9Skin, liver, lung, adrenal, small intestinePDAsthenia, anorexia, thrombocytopenia12.9
2F3701.5 NIVSCnod12009413.35Skin, LN, lungPR then PDAsthenia, myalgiasNausea, vomiting110a
3F7102 NIVSCnod3200929.0SkinPD3.05.7
4F640NIIICCnod147201021.87SkinCR100
5F410NIVSCnod5201020.23SC, lung, liver, colonPDAsthenia, myalgia, nausea3.3100a
6F7601.5 NIVCnod36201124.70SkinPD2.014.8
7F721NIVCnod62011222.90Skin, LN, bonePDAnorexia, rash3.012.3
8M8821.5 NIIICCnod2201224.20SkinSDAgeusia, asthenia, pruritus31.8
9F831NIIICCnod140201223.10Skin, LNPDAsthenia, flu-like syndrome4.98.4
10F730NIIICCnod0.75201223SkinSD then PDAnorexia, asthenia, flu-like syndrome7.945.0

AJCC: American Joint Committee on Cancer; Cnod: cutaneous nodule; CR: complete response; Skin: cutaneous; N: normal range; PD: progressive disease; PFS: progression-free survival; PR: partial response; PS: performance status; SD: stable disease; SC: subcutaneous; SCnod: subcutaneous nodule. aOngoing.